electroCore Inc ECOR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Randomized Study of Non-Invasive Autonomic Neuromodulation for Long COVID Published Online in Neuromodulation
electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
electroCore Announces Third Quarter 2026 Financial Results
electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026
electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)
fMRI Study Suggests Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) Accelerates Neural Processes in Visual Skill Learning
electroCore to Present at Planet MicroCap Toronto 2026 powered by MicroCapClub
electroCore to Participate at H.C. Wainwright Global Investment Conference
Trading Information
- Previous Close Price
- $4.85
- Day Range
- $3.90–4.97
- 52-Week Range
- $3.90–12.70
- Bid/Ask
- $4.42 / $5.55
- Shares Outstanding
- 9.23M
- Market Cap
- $40.78M
- Volume/Avg
- 631,593 / 120,518
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.08
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 83
- Website
- https://www.electrocore.com
Valuation
Metric | ECOR |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 1.08 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ECOR |
|---|---|
Quick Ratio | 0.85 |
Current Ratio | 1.34 |
Interest Coverage | −8.95 |
Quick Ratio
ECOR
Profitability
Metric | ECOR |
|---|---|
Return on Assets (Normalized) | −55.14% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −130.71% |
Return on Assets
ECOR
Medical Devices Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | LOCK|vschR<q | LOCK|N>%S? | $178B | |||
| Medtronic PLC MDT | LOCK|!?w#c% | LOCK|<!LJ | $128B | |||
| Stryker Corp SYK | LOCK|BD%dP$@! | LOCK|Hl | $118B | |||
| Boston Scientific Corp BSX | LOCK|R!l!<fx | LOCK|w##rR | $61B | |||
| Edwards Lifesciences Corp EW | LOCK|>n>$$MZ | LOCK|Yd$vN | $59B | |||
| GE HealthCare Technologies Inc Common Stock GEHC | LOCK|St!pL$ | LOCK|<> | $36B | |||
| DexCom Inc DXCM | LOCK|k$H@XY%J | LOCK|#&CV | $30B | |||
| Koninklijke Philips NV ADR PHG | LOCK|V$< | LOCK|>Y | $28B | |||
| Steris PLC STE | LOCK|<T>V@Yx | LOCK|nNK! | $25B | |||
| Zimmer Biomet Holdings Inc ZBH | LOCK|r@V%G<^j | LOCK|M^> | $19B |